U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06955169) titled 'Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma' on April 22.
Brief Summary: This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Intracranial Meningioma
Intervention:
DRUG: [177Lu]Lu-DOTATATE
The treatment regimen consists of 4 (+2 optional) administrations of 177Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
OTHER: Standard of Care treatments
Treatments will o...